Overview

A Study to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients with COPD

Status:
RECRUITING
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of HL231 Solution for Inhalation vs Ultibro in Chinese patients with moderate to very severe COPD
Phase:
PHASE3
Details
Lead Sponsor:
Haisco Pharmaceutical Group Co., Ltd.
Collaborator:
Sichuan Haisco Pharmaceutical Group Co., Ltd
Treatments:
Inhalation